Latest Financials News

Page 984 of 1667
Genesis Energy reported a robust FY25 with a 14% rise in normalised EBITDAF and a 29% jump in net profit, driven by strategic portfolio flexibility amid volatile energy markets. The company accelerated its Gen35 strategy, including key renewable projects and long-term capacity contracts to bolster New Zealand’s energy security.
Maxwell Dee
Maxwell Dee
26 Aug 2025
Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.
Maxwell Dee
Maxwell Dee
25 Aug 2025
Energy Transition Minerals Ltd has successfully raised $8 million through a heavily oversubscribed Share Purchase Plan, closing early due to strong shareholder demand. The funds will support the company’s critical minerals development strategy in Europe.
Maxwell Dee
Maxwell Dee
25 Aug 2025
Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.
Victor Sage
Victor Sage
25 Aug 2025
Acrow Limited reported a 23% revenue increase to $265.1 million for FY25, driven by strong growth in its Industrial Access division and key acquisitions. Despite a slight dip in earnings per share, the company declared a fully franked final dividend of 2.95 cents per share.
Victor Sage
Victor Sage
25 Aug 2025
Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.
Sophie Babbage
Sophie Babbage
25 Aug 2025
Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.
Ada Torres
Ada Torres
25 Aug 2025
Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.
Ada Torres
Ada Torres
25 Aug 2025
Goodman Group has announced a total distribution of 15 cents per stapled security for the year ended 30 June 2025, combining dividends from its Hong Kong logistics arm and its Australian industrial trust.
Eva Park
Eva Park
25 Aug 2025
Supply Network Limited reported a robust 15.5% revenue increase to $349.9 million and a 21.2% rise in profit after tax to $40 million for FY2025, alongside a higher fully franked final dividend of 38 cents per share.
Victor Sage
Victor Sage
25 Aug 2025
Symal Group Limited reported a robust FY25 with revenue and earnings growth exceeding Prospectus forecasts, underpinned by strategic acquisitions and a strong pipeline of contracts.
Victor Sage
Victor Sage
25 Aug 2025
Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.
Victor Sage
Victor Sage
25 Aug 2025